Versant Ventures, a healthcare venture capital firm, led a €80m Series A round in Antag Therapeutics, a biopharmaceutical company pioneering novel treatments for obesity, with participation from Novo Holdings, SR One, KKR, Pictet, Longview Ventures and Export and Investment Fund of Denmark. "The backing of such a strong syndicate of global investors is a testament to our pioneering approach to developing novel therapies for patients with obesity. Coupled with our recent IND clearance, this investment allows us to accelerate the development of AT-7687 towards important clinical milestones. We believe our first-in-class peptide's weight loss profile and flexible dosing will be key drivers of differentiation," Alexander Hovard Sparre-Ulrich, Antag CEO and Co-Founder.